Investigating how CD40 immunotherapy affects heart immune responses and myocardial disease.
CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
This study is looking at how a treatment called CD40 immunotherapy affects the heart's immune system, especially for people with heart issues who are also receiving cancer treatments, to see if it might cause any heart problems.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10988312 on NIH RePORTER |
What this research studies
This research explores the effects of CD40 immunotherapy on the immune landscape of the heart, particularly in relation to myocardial disease. It aims to understand how CD40 signaling can activate immune responses that may lead to cardiac injury, especially in patients undergoing cancer treatment with immune checkpoint inhibitors. By examining the interactions between antigen-presenting cells and T-cells, the study seeks to identify mechanisms that could contribute to adverse cardiac events. Patients may be monitored for changes in heart health and immune responses during the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving immunotherapy who may be at risk for cardiac complications.
Not a fit: Patients not undergoing immunotherapy or those without existing heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer immunotherapy options for cancer patients, minimizing the risk of heart-related side effects.
How similar studies have performed: While immunotherapy has shown success in treating cancer, the specific effects of CD40 agonists on cardiac health are still being explored, making this research a novel investigation.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Jimenez, Jesus — Washington University
- Study coordinator: Jimenez, Jesus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.